GCISkinBioTherapeutics to launch AxisBiotix-Ps™ on Amazon UK
The supplement targeting sensitive skin like psoriasis has seen strong UK sales (80% retention) since its 2021 debut. Leveraging Amazon's wide reach aligns with a strategy to simplify access and boost sales, tapping into a market where 90% of UK adults shop.
Stuart J. Ashman, CEO of SkinBioTherapeutics, said: "The skin care market is a significant market, with an increasing global focus on health and well-being, and the demand for science-backed supplements is at an all-time high. The primary focus for AxisBiotix-Ps™ is growing our share of the market and using a sales channel like Amazon, which we use everyday, makes good strategic sense. We hope to announce the European launches on Amazon before the end of the year."
Follow SkinBioTherapeutics for more News and Updates:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.